deferasirox has been researched along with Cancer of Esophagus in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedford, MR; Ford, SJ; Iqbal, T; Pang, W; Tselepis, C; Tucker, O; Wood, A | 1 |
| Fujiwara, T; Nishitani, S; Noma, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Watanabe, S | 1 |
| Alderson, D; Bedford, M; Chadwick, C; Ford, SJ; Iqbal, TH; Jansson, PJ; Kalinowski, DS; Lovejoy, DB; Lui, GY; Nichols, L; Obeidy, P; Richardson, DR; Tselepis, C; Tucker, O | 1 |
| Brookes, MJ; Keeler, BD | 1 |
4 other study(ies) available for deferasirox and Cancer of Esophagus
| Article | Year |
|---|---|
A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.
Topics: Adenocarcinoma; Aged; Anemia, Iron-Deficiency; Benzoates; Chelation Therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deferasirox; Esophageal Neoplasms; Esophagectomy; Female; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Male; Patient Selection; Prospective Studies; Triazoles | 2014 |
Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer.
Topics: Animals; Benzoates; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deferasirox; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Iron Deficiencies; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Phenotype; Triazoles | 2016 |
Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deferasirox; Deferoxamine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagus; Female; Humans; Iron; Iron Chelating Agents; Mice; Mice, Inbred BALB C; Mice, Nude; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Iron chelation: a potential therapeutic strategy in oesophageal cancer.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Proliferation; Deferasirox; Esophageal Neoplasms; Esophagus; Female; Humans; Iron Chelating Agents; Triazoles | 2013 |